R. Michael Blaese

R. Michael Blaese's AcademicInfluence.com Rankings

R. Michael Blaese

Philosophy

#6067

World Rank

#9036

Historical Rank

Logic

#3261

World Rank

#4391

Historical Rank

philosophy Degrees

Download Badge

Philosophy

R. Michael Blaese's Degrees

PhD Microbiology University of Washington
Bachelors Biology University of California, San Diego

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is R. Michael Blaese Influential?

(Suggest an Edit or Addition)

(See a Problem?)

R. Michael Blaese's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. (1992) (1569)
T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years (1995) (1412)
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells (1997) (696)
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. (1974) (633)
A multiinstitutional survey of the Wiskott-Aldrich syndrome. (1994) (597)
Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiency (1995) (594)
Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. (1992) (526)
In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. (1993) (474)
Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. (1993) (417)
Improved methods of retroviral vector transduction and production for gene therapy. (1994) (401)
T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates (1998) (325)
Immune response to B19 parvovirus and an antibody defect in persistent viral infection. (1989) (318)
High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. (1995) (266)
Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. (1997) (266)
Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. (1994) (247)
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. (2012) (229)
Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. (1978) (222)
Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. (1981) (215)
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. (2000) (214)
Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. (1988) (211)
The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. (1995) (209)
Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. (2003) (205)
Immunodeficiency disease and malignancy. Various immunologic deficiencies of man and the role of immune processes in the control of malignant disease. (1972) (204)
The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. (1990) (202)
Gene therapy of cancer. (1994) (194)
Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. (1999) (190)
Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. (1984) (184)
Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer (1999) (180)
The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. (1994) (173)
The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. (1968) (172)
X-linked hypogammaglobulinemia and isolated growth hormone deficiency. (1980) (170)
Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. (2002) (169)
Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. (1990) (160)
Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus. (1980) (159)
The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity. (1976) (152)
Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. (1998) (149)
Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. (1979) (148)
Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. (1990) (147)
Structural and functional basis for JAK3-deficient severe combined immunodeficiency. (1997) (146)
Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. (1984) (139)
Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. (1996) (139)
Lymphocytes as cellular vehicles for gene therapy in mouse and man. (1991) (136)
Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. (2014) (136)
Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome. (1980) (135)
Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment (1997) (134)
Epstein-Barr virus infection and immunoregulation in man. (1985) (133)
Defective lymphocyte transformation and delayed hypersensitivity in Wiskott-Aldrich syndrome. (1970) (131)
Lymphocyte gene therapy. (1991) (130)
Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent (1989) (128)
The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. (2002) (127)
Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults (1998) (125)
A receptor for IgA on human T lymphocytes. (1979) (122)
Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features. (1990) (118)
Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. (1992) (115)
Isolation of papovavirus from brain tumor and urine of a patient with Wiskott-Aldrich syndrome. (1974) (114)
Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). (1985) (111)
B cell differentiation and immunoregulatory T cell function in human cord blood lymphocytes. (1980) (110)
Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. (1998) (109)
Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. (1993) (107)
The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication (1998) (106)
INFECTIOUS AGAMMAGLOBULINEMIA: TRANSMISSION OF IMMUNODEFICIENCY WITH GRAFTS OF AGAMMAGLOBULINEMIC CELLS (1974) (106)
Monocyte-mediated antibody-dependent cellular cytotoxicity: a clinical test of monocyte function. (1976) (104)
Identification of mutations in the Wiskott-Aldrich syndrome gene and characterization of a polymorphic dinucleotide repeat at DXS6940, adjacent to the disease gene. (1995) (101)
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells (1983) (101)
Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism. (1971) (100)
Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. (1993) (99)
Relationship between immunoglobulin production and immortalization by Epstein Barr virus. (1985) (99)
Immunoglobulin production induced in vitro by glucocorticoid hormones: T cell-dependent stimulation of immunoglobulin production without B cell proliferation in cultures of human peripheral blood lymphocytes. (1981) (98)
In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. (1994) (96)
Malignant lymphoma in patients with the Wiskott-Aldrich syndrome. (1985) (90)
Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases (1993) (87)
Immunoglobulin secreting cells in normal human bronchial lavage fluids. (1978) (87)
Abnormalities of chemotactic lymphokine synthesis and mononuclear leukocyte chemotaxis in Wiskott-Aldrich syndrome. (1974) (87)
Defective mononuclear leukocyte chemotaxis: a previously unrecognized immune dysfunction. Studies in a patient with chronic mucocutaneous candidiasis. (1973) (85)
IMMUNODEFICIENCY IN FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS (1978) (83)
Platelet-associated immunoglobulin, platelet size, and the effect of splenectomy in the Wiskott-Aldrich syndrome. (1985) (83)
Development of Gene Therapy for Immunodeficiency: Adenosine Deaminase Deficiency (1993) (81)
Carrier detection in the Wiskott Aldrich syndrome (1988) (80)
Impaired lymphocyte transformation in intestinal lymphangiectasia: evidence for at least two functionally distinct lymphocyte populations in man. (1972) (75)
Retroviral-mediated gene correction for X-linked severe combined immunodeficiency. (1996) (73)
Human gene marker/therapy clinical protocols. (1996) (73)
Suppression of the human autologous mixed lymphocyte reaction by physiologic concentrations of hydrocortisone. (1977) (70)
Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. (2005) (69)
In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction (1996) (69)
Selective inhibition of immunoregulatory cell functions by cyclosporin A. (1982) (67)
Acyclovir treatment of the chronic fatigue syndrome. (1988) (66)
Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. (1991) (66)
Soluble suppressor supernatants elaborated by concanavalin A-activated human mononuclear cells. II. Characterization of a soluble suppressor of B cell immunoglobulin production. (1981) (65)
A simple and reliable method for screening retroviral producer clones without selectable markers. (1997) (63)
Phytohemagglutinin as a skin test for the evaluation of cellular immune competence in man. (1973) (60)
Development of Improved Adenosine Deaminase Retroviral Vectors (1998) (59)
IMMUNOLOGIC INCOMPETENCE OF IMMUNOLOGICALLY RUNTED ANIMALS. (1964) (59)
T cell-mediated immunoregulation of Epstein Barr virus- (EBV) induced B lymphocyte activation in EBV-seropositive and EBV-seronegative individuals. (1982) (58)
Gene therapy for cancer. (1997) (57)
Intrathecal gene therapy for malignant leptomeningeal neoplasia. (1994) (57)
Ontogeny of humoral immune function in normal chickens: a comparison of immunoglobulin-secreting cells in bone marrow, spleen, lungs and intestine. (1981) (54)
Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. (2003) (52)
Infection of human cells with murine amphotropic replication-competent retroviruses. (1993) (51)
Evidence that specific oligosaccharides block early events necessary for the expression of antigen-specific proliferation by human lymphocytes. (1980) (51)
Human gene marker/therapy clinical protocols. (1999) (51)
Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector. (1996) (51)
Granulocyte colony-stimulating factor recruitment of CD34+ progenitors to peripheral blood : Impaired mobilization in chronic granulomatous disease and adenosine deaminase-deficient severe combined immunodeficiency disease patients (1996) (51)
In vivo expression and survival of gene-modified T lymphocytes in rhesus monkeys. (1990) (50)
Increased bronchoalveolar IgG-secreting cells in interstitial lung diseases. (1980) (50)
The origin of salivary IgA. (1970) (49)
Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott–Aldrich syndrome patients carrying ‘null’ mutations (1999) (47)
Immunoregulatory properties of fractions from human pregnancy urine: evidence that human chorionic gonadotropin is not responsible. (1977) (45)
Scanning of the Wiskott-Aldrich syndrome (WAS) gene: identification of 18 novel alterations including a possible mutation hotspot at Arg86 resulting in thrombocytopenia, a mild WAS phenotype. (1995) (45)
Adeno-retroviral chimeric viruses as in vivo transducing agents (1999) (44)
Constrictive pericarditis, intestinal lymphangiectasia, and reversible immunologic deficiency. (1975) (43)
Familial chronic lymphocytic leukemia. Immunologic and cellular characterization. (1976) (43)
Variable immunodeficiency with abnormal condensation of the heterochromatin of chromosomes 1, 9, and 16. (1988) (43)
Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion. (1997) (42)
Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. (1999) (42)
Fc receptors for IgA on human B, and human non-B, non-T lymphocytes. (1979) (41)
Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1 (1997) (40)
A reappraisal of the effector cells mediating mitogen induced cellular cytotoxicity. (1975) (40)
Carrier detection in the Wiskott Aldrich syndrome. (1988) (39)
Immunodeficiency in the Wiskott-Aldrich syndrome. (1975) (39)
Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants. (2010) (39)
Efficient directional cloning of recombinant adenovirus vectors using DNA-protein complex. (1998) (38)
Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide. (1981) (38)
Establishment and characterization of adenosine deaminase-deficient human T cell lines. (1989) (37)
Artifactual plaque formation in vitro and in vivo to passive transfer of specific antibody. (1976) (37)
Long-term remission from acute myelogenous leukemia after bone marrow transplantation and recovery from acute graft-versus-host reaction and prolonged immunoincompetence. (1975) (37)
Defibrination syndrome in an infantborn after abruptio placentae (1968) (36)
Lymphocyte-macrophage interaction in antigen induced in vitro lymphocyte transformation in patients with the Wiskott-Aldrich syndrome and other diseases with anergy. (1972) (36)
Antibodies to nucleic acids in congenital immune deficiency states. (1976) (36)
Cooperative interaction of factor B and other complement components with mononuclear cells in the antibody-independent lysis of xenogeneic erythrocytes (1982) (35)
Functional properties of human T cells bearing Fc receptors for IgA. I. Mitogen responsiveness, mixed lymphocyte culture reactivity, and helper activity for B cell immunoglobulin production. (1980) (35)
Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992. (1993) (35)
Granulocyte colony-stimulating factor recruitment of CD34+ progenitors to peripheral blood: impaired mobilization in chronic granulomatous disease and adenosine deaminase--deficient severe combined immunodeficiency disease patients. (1996) (35)
Keratinocyte gene therapy for adenosine deaminase deficiency: a model approach for inherited metabolic disorders. (1997) (34)
Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. (1999) (34)
Normalization of antibody responsiveness in a patient with common variable hypogammaglobulinemia and HIV infection. (1987) (34)
In situ delivery of suicide genes for cancer treatment. (1994) (34)
POKEWEED MITOGEN-, CONCANAVALIN A-, AND PHYTOHEMAGGLUTININ-INDUCED DEVELOPMENT OF CYTOTOXIC EFFECTOR LYMPHOCYTES (1973) (33)
A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. (2000) (33)
Spontaneous cytotoxicity of human peripheral mononuclear cells toward red blood cell targets in vitro. I. characterization of the killer cell. (1977) (33)
Hereditary thrombocytopenia: relation to Wiskott-Aldrich syndrome with special reference to splenectomy. Report of a family and review of the literature. (1972) (33)
Pure red blood cell aplasia associated with chronic Epstein-Barr virus infection: evidence for T cell-mediated suppression of erythroid colony forming units. (1984) (32)
Gene Therapy for Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: Improved Retroviral Vectors for Clinical Trials (1999) (31)
Newborn and Wiskott-Aldrich patient B cells can be activated by TNP-Brucella abortus: evidence that TNP-Brucella abortus behaves as a T-independent type 1 antigen in humans. (1984) (31)
The Wiskott-Aldrich syndrome protein (1996) (30)
Development of a skin-based metabolic sink for phenylalanine by overexpression of phenylalanine hydroxylase and GTP cyclohydrolase in primary human keratinocytes (2000) (30)
Patients with Wiskott-Aldrich syndrome have normal IgG2 levels. (1986) (30)
Interferon-mediated inhibition of human polyclonal immunoglobulin synthesis. (1982) (28)
Intrathecal Gene Therapy for the Treatment of Leptomeningeal Carcinomatosis. National Institutes of Health, Bethesda, Maryland (1995) (28)
Adenovirus vectors as transcomplementing templates for the production of replication defective retroviral vectors. (1998) (28)
Hereditary sensory neuropathy. Association with increased synthesis of immunoglobulin A. (1974) (27)
Monoclonal gammopathy in the Wiskott-Aldrich syndrome. (1974) (26)
T cell-replacing factor for glucocorticosteroid-induced immunoglobulin production. A unique steroid-dependent cytokine (1983) (26)
Retrovirus-mediated gene transfer of ornithine-delta-aminotransferase into keratinocytes from gyrate atrophy patients. (1997) (24)
Retroviral expression of recombinant p47phox protein by Epstein-Barr virus-transformed B lymphocytes from a patient with autosomal chronic granulomatous disease. (1992) (24)
IMMUNOLOGIC INCOMPETENCE OF IMMUNOLOGICALLY RUNTED ANIMALS (1964) (24)
Strategies for gene therapy. (1993) (24)
Suppressor T cell clones from patients with acute Epstein-Barr virus-induced infectious mononucleosis. (1987) (24)
A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. (1993) (23)
Spontaneous cytotoxicity of human peripheral blood mononuclear cells toward red blood cell targets. II. Time-dependent loss of suppressor cell activity. (1977) (23)
Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-producer cells. (1995) (22)
Progress toward gene therapy. (1991) (22)
Purification and characterization of a mannose-containing disaccharide obtained from human pregnancy urine. A new immunoregulatory saccharide (1984) (22)
Tissue distribution of immunoglobulin-secreting cells in normal and IgA-deficient chickens. (1979) (22)
Induction of cytotoxic effector activity in the HL-60 promyelocytic cell line by incubation with phorbol myristate acetate: a model system of human spontaneous monocyte-mediated cytotoxicity. (1983) (21)
Immunologic deficiency diseases. (1971) (21)
Characterization of a soluble suppressor of human B cell immunoglobulin biosynthesis produced by a continuous human suppressor T cell line (1981) (21)
Increased sensitivity of lymphocyte Δ1pyrroline-5-carboxylate reductase to inhibition by proline with transformation (1975) (21)
Gene therapy for primary immunodeficiency disease. (1992) (20)
Cytotoxic effector cell function in organized gut-associated lymphoid tissue (GALT). (1976) (19)
Reversal of infectious mononucleosis-associated suppressor T cell activity by D-mannose (1983) (19)
Infectious agammaglobulinemia: suppressor T cells with specificity for individual immunoglobulin classes. (1977) (18)
The cytotoxic effector potential of some common non-lymphoid tumors and cultured cell lines with phytohemagglutinin and heterologous anti-erythrocyte antisera. (1975) (18)
Gene therapy: lessons learnt from the past decade (1999) (18)
Spontaneous cytotoxicity by human peripheral blood monocytes: inhibition by monosaccharides and oligosaccharides. (1981) (17)
Gene transfer and expression in nonhuman primates using retroviral vectors. (1986) (17)
TNF/TIL Human Gene Therapy Clinical Protocol: Original Protocol, April 23, 1990 (1990) (16)
Production of macrophage migration inhibitory factor and lymphotoxin by leukocytes from normal and Wiskott-Aldrich syndrome patients. (1973) (16)
The effect of Mycobacterium bovis (Bacillus Calmette-Guérin) on macrophage random migration, chemotaxis, and pinocytosis. (1976) (16)
The mononuclear phagocyte system: role in expression of immunocompetence in neonatal and adult life. (1979) (16)
Generation of a conditionally neor-containing retroviral producer cell line: effects of neor on retroviral titer and transgene expression (1998) (15)
A high-resolution map of genes, microsatellite markers, and new dinucleotide repeats from UBE1 to the GATA locus in the region Xp11.23. (1995) (15)
Inhibition of antigen-stimulated in vitro proliferation of thymic dependent chicken spleen cells by specific antibody. (1972) (15)
Immunostimulation by cytomegalovirus (CMV): helper T cell-dependent activation of immunoglobulin production in vitro by lymphocytes from CMV-immune donors. (1985) (14)
Inhibition of human lymphoproliferation by intravenous lipid emulsion. (1982) (14)
Ophthalmic manifestations of the Wiskott-Aldrich syndrome. (1969) (14)
Malignant lymphoma of the jejunum in a patient with Wiskott-Aldrich syndrome. Surgical treatment. (1975) (14)
A novel approach using transcomplementing adenoviral vectors for gene therapy of adrenocortical cancer. (2002) (14)
EVIDENCE THAT MONOCYTE MEDIATED CELLULAR RECOGNITION PHENOMENA ARE MEDIATED BY RECEPTORS WITH SPECIFICITY FOR SIMPLE OLIGOSACCHARIDES (1980) (14)
Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction. (1994) (13)
Synergistic cytotoxicity. I. Characterization of a heat labile plasma fraction that induces nonspecific cytotoxicity by human mononuclear cells. (1979) (13)
IMMUNODEFICIENCY IN FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS (1978) (12)
Immunosuppressive activity of succinylacetone. (1982) (12)
Effect of Corynebacterium parvum, methanol-extraction residue of BCG, and levamisole on macrophage random migration, chemotaxis, and pinocytosis. (1977) (12)
Defibrination syndrome in an infant born after abruptio placentae. (1968) (12)
Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer (2000) (12)
MICC cytotoxic effector function of human T lymphocyte subpopulations bearing Fc-receptors for IgG and IgM. (1979) (12)
Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells. (2001) (11)
Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. GTI 0108. A phase I/II study. (1995) (11)
Uromodulin: a specific inhibitor of IL-1-initiated human T cell colony formation. (1990) (11)
Enhanced cAMP production by activated human Fc-IgG receptor positive T-cell subpopulations. (1981) (11)
Hemolytic anemia in agammaglobulinemic chickens: a model of "autoimmune" disease in immune deficiency. (1971) (10)
Spontaneous cytotoxicity. III. Inhibition of human monocyte mediated cytotoxicity by pokeweed mitogen. (1979) (10)
Synergistic cytotoxicity. II. In vitro arming of monocytes and T cells by a heat labile fraction of human plasma. (1979) (10)
17 – PHYSIOLOGICAL FACTORS CONTROLLING IMMUNOGLOBULIN METABOLISM (1970) (10)
Lack of effector cell function in chronic lymphocytic leukemia, a B-cell malignancy, and the Sézary syndrome, a T-cell malignancy. (1978) (10)
Reconstitution of immunologic function in a patient with severe combined immunodeficiency following transplantation of marrow from an HLA-A,B,C nonidentical but MLC-compatible paternal donor. (1979) (9)
Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer. (1998) (9)
Gene Therapy for Adenosine Deaminase Deficiency and Malignant Solid Tumors (1994) (9)
Human gene marker/therapy clinical protocols. (1997) (9)
The treatment of adenosine deaminase deficiency. (1987) (9)
What is the status of gene therapy for primary immunodeficiency? (2007) (9)
Suppressor T-cell function in man: suppression of immunoglobulin production by the direct action of immunoregulatory T cells on the B cell in four separate, distinct systems. (1982) (8)
T3-T cell receptor (Ti) complex-independent activation of T cells by wheat germ agglutinin. (1987) (8)
Lymphoid populations of gut mucosa in chickens (1980) (8)
Immunosuppression by succinylacetone. II. Prevention of graft-vs-host disease. (1987) (8)
WISKOTT-ALDRICH SYNDROME (WAS) CARRIER DETECTION BY X-CHROMOSOME INACTIVATION ANALYSIS (1987) (8)
Immunization Of The Immunocompromised Host (1998) (7)
Gene therapy for genetic diseases. (1989) (7)
Immunoglobulin metabolism in disease. (1975) (7)
The role of nonactivated and interferon-gamma activated monocytes in regulating normal and SLE patient B cell responses to TNP-Brucella abortus. (1986) (7)
Steps toward gene therapy: 2. Cancer and AIDS. (1995) (7)
Cellular distribution of a human I-A-like (DS/DC) antigen on normal and neoplastic lymphoid cells. (1985) (7)
Steps toward gene therapy: 1. The initial trials. (1995) (7)
Treatment of experimental autoimmune uveitis in the rat with systemic succinylacetone. (1988) (7)
18 Suicide Genes: Gene Therapy Applications Using Enzyme/Prodrug Strategies (1999) (6)
Brain tumor treatment: significant contributions. (1992) (6)
A CRITIQUE OF TECHNIQUES OF MACROPHAGE-MONOCYTE DEPLETION IN STUDIES OF HUMAN PERIPHERAL BLOOD MONONUCLEAR LEUKOCYTE (MNL) FUNCTION (1977) (6)
Phytohaemagglutinin-induced cytotoxic effector lymphocyte function in patients with the Wiskott-Aldrich syndrome (WAS). (1973) (6)
The role of cell surface lectin--carbohydrate interactions in cellular recognition, cooperation, and regulation. (1983) (6)
Synergistic Cytotoxicity (1979) (6)
Differential effects of ouabain on human cell-mediated cytotoxicity. I. Inhibition of mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity against chicken red cell targets. (1979) (6)
Enumeration of pulmonary immunoglobulin secreting cells in human bronchoalveolar lavage. (1979) (6)
Optimism regarding the use of RNA/DNA hybrids to repair genes at high efficiency (1999) (6)
Retroviral-mediated gene transfer into hemopoietic cells. (1988) (5)
Infection of human hematopoietic progenitor cells using a retroviral vector with a xenotropic pseudotype. (1988) (5)
Monocyte cytotoxicity: evidence for multiple mechanisms of in vitro erythrocyte target killing. Trypan blue can both inhibit and enhance target lysis. (1982) (5)
Seasonal viral influenza among persons with primary antibody immunodeficiency. (2019) (5)
Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency. (1995) (5)
Evidence of two functionally distinct lymphocyte populations in man. (1973) (5)
Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells (1991) (5)
Lymphokine induction of DR Antigen expression on human neonatal and cell line monocytes (1982) (5)
Gene therapy for cancer. (1997) (5)
712 SPLENECTOMY AND PROPHYLACTIC ANTIBIOTICS IN THE MANAGEMENT OF THE WISKOTT-ALDRICH SYNDROME (WAS) (1978) (4)
Macrophage function in the development of immunocompetence and in immunodeficiency. (1976) (4)
Gene therapy of primary immunodeficiencies (2004) (4)
THE USE OF GENE THERAPY FOR IMMUNODEFICIENCY DISEASE (1996) (3)
CHAPTER 21 – IMMUNOGLOBULIN SECRETING CELLS IN THE CIRCULATING BLOOD AND IN MITOGEN STIMULATED CULTURES FROM PATIENTS WITH IMMUNODEFICIENCY DISEASES (1979) (3)
Characterization of T cell ligands for uromodulin: a possible role in costimulation. (1994) (3)
A MONOCLONAL ANTIBODY DIRECTED AGAINST A HUMAN B LYMPHOID CELL ACTIVATION ANTIGEN (1982) (3)
Hepatitis B virus infection in the Wiskott-Aldrich syndrome. (1976) (3)
Differential effects of ouabain on human cell-mediated cytotoxicity. II. Stimulation of monocyte-mediated, spontaneous cytotoxicity against chicken red cell targets. (1979) (3)
18 – ABNORMALITIES OF IMMUNOGLOBULIN METABOLISM (1970) (2)
Defective allosuppression in patients with ataxia-telangiectasia. (1985) (2)
Lymphoid cell-derived lectin-like receptor molecules as immunoregulatory signals in immunodeficiency. (1983) (2)
Disorders of Suppressor T Cells in Immunodeficiency and Malignancy (1980) (2)
thrombocytopenia are caused by mutations of the same gene The Wiskott-Aldrich syndrome and X-linked congenital (2011) (2)
Inhibition of human lymphoproliferative responses and altered lymphocyte membrane phenotype by succinylacetone. (1992) (1)
Immunodeficiency Disease and Malignancy (2020) (1)
Challenges of Genetic Disease: Gene Addition or Gene Repair (1999) (1)
Immune Assessment of Patients with Chronic Active EBV Infection (CAEBV) (1985) (1)
The proportion of TA, TG, and TM cells in various immunodeficiency and autoimmune disorders. (1983) (1)
Phytohemagglutinin (PHA) skin test: A measure of intact cellmediated immunity (1971) (1)
Monoclonal gammopathy in syndrome the Wiskott-Aldrich (1974) (1)
TWO COLOR FLOW CYTOMETRIC ANALYSIS OF CORD BLOOD LYMPHOCYTES (1987) (1)
General Discussion 2 (1994) (1)
Comparison of Anti-HIV-1 Retroviral Vectors and Their Use in a Gene Therapy Trial in Identical Twins (1995) (0)
685 IMMUNOGLOBULIN SECRETING CELLS IN THE BLOOD AND TONSIL OF NORMALS AND PATIENTS WITH IMMUNODEFICIENCY (1978) (0)
Natural gene therapy: Somatic reversion in the Wiskott–Aldrich syndrome (2008) (0)
920 EFFECTS OF STEROID HORMONES ON IMMUNOGLOBULIN PRODUCTION IN ADULT AMD CORD BLOOD LYMPHOCYTES (1981) (0)
EVALUATION OF RETROVIRAL MEDIATED GENE TRANSFER BY IN SITU HYBRIDIZATION (1987) (0)
I Brief Definitive Reports I INFECTIOUS AGAMMAGLOBULINEM IA: TRANSMISSION OF IMMUNODEFICIENCY WITH GRAFTS OF AGAMMAGLOBULINEM IC CELLS (1974) (0)
results of the first clinical gene therapy trial years and immune reaction to gene transfer components: Long-term Persistence and expression of the adenosine deaminase gene for twelve (2013) (0)
Corrigendum: Retroviral transfer of acid α-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion (Human Gene Therapy (1997) 8, 13 (1555-1563)) (1998) (0)
Human gene marker/therapy clinical protocols. (2000) (0)
AbstractDevelopment of gene therapy for mesothelioma using the Herpes simplex thymidine kinase suicide gene system (1996) (0)
Neel Distinguished Research Lecturer: Where We Stand with Gene Therapy (1997) (0)
Clinical Protocol Amendment to Clinical Research Project Project 90-C-195 (1999) (0)
AN EVALUATION OF THE MECHANISMS OF T CELL-MEDIATED CYTOTOXICITY BY HOLGER KIRCHNER AND R. MICHAEL BLAESE (2003) (0)
SPLICE SITE MUTATIONS IN THE WISKOTT ALDRICH SYNDROME. • 59 (1996) (0)
Retroviral-Mediated Transfer andExpression of the Common Gamma Chain intoHuman Hematopoietic Progenitors (1999) (0)
Human gene marker/therapy clinical protocols. (1996) (0)
The Effect of Mycobacteriumbovis(BacillusCalmetteGuÃ«rin) on Macrophage RandomMigration,Chemotaxis,and Pinocytosis1 (1976) (0)
features (see comments) clinical of a subset of patients with distinctive immunophenotypic and Characterization of common variable immunodeficiency: identification (2011) (0)
Reversal of Common Variable Hypogammaglobulinemia-Associated Suppressor Cell Activity by Specific Carbohydrates (1985) (0)
IMMUNOGLOBULIN CLASS SPECIFIC SUPPRESSOR T CELLS (1977) (0)
In situ gene delivery for cancer therapy (1995) (0)
Disorders of the immunoglobulin A system in hereditary sensory neuropathy. (1973) (0)
GENE THERAPY (1996) (0)
Deaminase Deficiency With Severe Combined Immune Deficiency Caused by Adenosine Directed Gene Transfer for a Patient - Successful Peripheral T-Lymphocyte (2011) (0)
Monocyte Contrasuppression of EBV-Immune Regulatory T Cells (1985) (0)
The wiskott aldrich syndrome gene localization and carrier detection with restriction fragment length polymorphisms (1986) (0)
Antibodies to nucleic acids deficiency states in congenital immune (1976) (0)
The mononuclear phagocyte system: the heart of host defense. (1986) (0)
Contribution of B and T lymphocytes to in vitro chicken proliferative spleen cell reactions to antigens. (1973) (0)
FAVORABLE RESPONSE TO IVIgG IN A WISCOTT-ALDRICH SYNDROME INFANT WITH SEVERE THROMBOCYTOPENIA REFRACTORY TO SPLENECTOMY (1987) (0)
951 IMPAIRED SPECIFIC IN VITRO ANTIBODY RESPONSES IN PATIENTS WITH ATAXIA TELANGIECTASIA (A-T) (1981) (0)
Terapia genowa nowotworow i AIDS (1997) (0)
85. Von Willebrand Factor (VWF) Gene Targeting by Double_Strand Break Enhanced Homologous Recombination (2006) (0)
Gene therapy of cancer. (1994) (0)
OVERCORNING THE OBSTACLES (1997) (0)
1040. Towards Gene Correction Therapy for Wiskott-Aldrich Syndrome Using Designed Zinc Finger Endonucleases (2006) (0)
Gene Therapy for Cancer Inserted genes could in theory arrest tumor growth or even AIDS (0)
Gene Therapy for Immunodeficiency and Cancer (1993) (0)
IDF MEDICAL ADVISORY COMMITTEE (2013) (0)
Wait-effect in tumor-destructive therapy (1993) (0)
Alternative splicing of the Wiskott-Aldrich syndrome (WAS) gene may affect phenotype (1996) (0)
STUDIES OF MONOCYTE Fc RECEPTOR AVIDITY AND MONOCYTE MEDIATED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (MMADCC) IN MAN (1977) (0)
IMMUNODEFICIENCY IN LYMPHOHISTIOCYTOSIS: DEFECTIVE CELLULAR IMMUNITY IN ASSOCIATION WITH HYPERLIPIDEMIA (1977) (0)
Human gene marker/therapy clinical protocols. (1999) (0)
ESTABLISHMENT AND CHARACTERIZATION OF ADENOSINE DEAMINASE (ADA)-DEFICIENT T CELL LINES (1987) (0)
Prospects for gene therapy of human disease. (1991) (0)
patient with Wiskott-Aldrich syndrome Unprecedented diversity of genotypic revertants in lymphocytes of a (2012) (0)
SPONTANEOUS CYTOTOXICITY BY HUMAN PERIPHERAL BLOOD LYMPHOCYTES DUE TO A TIME DEPENDENT LOSS OF SUPPRESSOR CELLS (1977) (0)
New approaches in the therapy of immunodeficiency. (1993) (0)
Spontaneous Cytotoxicity (1979) (0)
Rapid Publication (2003) (0)
immunodeficiency Retroviral-mediated gene correction for X-linked severe combined (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With R. Michael Blaese?

R. Michael Blaese is affiliated with the following schools:

R. Michael Blaese's Academic­Influence.com Rankings